BI-4464
≥98%
- Product Code: 106077
CAS:
1227948-02-8
| Molecular Weight: | 555.55 g./mol | Molecular Formula: | C₂₈H₂₈F₃N₅O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
BI-4464 is primarily used in the field of cancer research, particularly in the study of acute myeloid leukemia (AML) and other hematologic malignancies. It functions as a potent and selective inhibitor of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1), which is often mutated in certain cancers. By targeting this mutation, BI-4464 helps to inhibit the production of the oncometabolite 2-hydroxyglutarate (2-HG), which drives cancer progression. This makes it a valuable tool for understanding the role of IDH1 mutations in tumorigenesis and for developing targeted therapies. Additionally, it is utilized in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent for IDH1-mutated cancers.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White Solid |
| Purity (%) | 97.5-100 |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $31.80 |
+
-
|
| 0.005 | 10-20 days | $80.41 |
+
-
|
| 0.010 | 10-20 days | $144.01 |
+
-
|
| 0.025 | 10-20 days | $277.83 |
+
-
|
BI-4464
BI-4464 is primarily used in the field of cancer research, particularly in the study of acute myeloid leukemia (AML) and other hematologic malignancies. It functions as a potent and selective inhibitor of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1), which is often mutated in certain cancers. By targeting this mutation, BI-4464 helps to inhibit the production of the oncometabolite 2-hydroxyglutarate (2-HG), which drives cancer progression. This makes it a valuable tool for understanding the role of IDH1 mutations in tumorigenesis and for developing targeted therapies. Additionally, it is utilized in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent for IDH1-mutated cancers.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :